Penumbra, Inc.
PENHealthcareNASDAQMedical Devices
Scan Results
Daily timeframePenumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company carries a $12.54B market cap, placing it firmly in the large-cap category. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.
Market Cap
$12.54B
Beta
0.73
P/E (TTM)
73.61
P/E (Fwd)
50.66
EPS (TTM)
$4.33
EPS (Fwd)
$6.29
ROE
12.7%
ROA
6.7%
Cash
$615.7M
Total Debt
$216.2M
Free CF
$141.8M
52W Change
24.8%
Annual Financials
Cash vs Debt
Penumbra, Inc. holds $615.7M in cash against $216.2M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Annual free cash flow of $141.8M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 12.7%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 6.7% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $847.1M (2022) to $1.40B (2025), reflecting a 66% increase over the period.
With cash comfortably exceeding debt, PEN has financial flexibility that may help navigate uncertain periods. At over 50x earnings, PEN carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Penumbra, Inc. and its sector.